EN
简体
繁体
EN
简体
繁体
About Us
Company Profile
Milestones
Our Team
Investors
Partnership & Recognition
Contact Us
CANbridge in Rare Disease Community
Pipeline & Products
Pipeline
Rare Diseases
Gene Therapy
Approved Products
Gaurunning®
Livmarli®
Hunterase®
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Corporate Governance
Stock Information
Presentations & Webcasts
Analyst Coverage
Financial Calendar
Email Alert and IR Contact
Electronic Dissemination of Corporate Communications
Media & News
Media Reports
Press Release
Corporate Culture & Career
Corporate Culture
Open Positions
Financial Reports
2025
2025 Interim Report
Interim Results Announcement for the Six Months Ended 30 June,2025
2024
2024 Annual Report
2024 ESG Report
Annual Results Announcement for The Year Ended December 31, 2024
2024 Interim Report
Interim Results Announcement for the Six Months Ended 30 June,2024
2023
2023 Annual Report
2023 ESG Report
Annual Results Announcement for The Year Ended December 31, 2023
2023 Interim Report
1
2